Censuses and Surveys' omnibus survey shows that only 2.1% of families with children contain children from both a previous and the current partner.¹ This proportion is low because, although many people change partners, they tend to do so after they have had most of their children. An unknown proportion of families with lone mothers contain two or more children of different fathers; if this proportion were half it would represent an extra 4% of all families with children. This would make the cost of the two screening methods similar.

The main reason, however, for preferring couple screening is not economic but medical.⁴ In sequential screening 97% of women who are positive on screening will have a partner who is negative, some of whom will carry a mutation for cystic fibrosis that cannot be detected. These women may resent the anxiety generated by being identified as a carrier, with the resultant increased risk of an affected pregnancy but no diagnostic test available to resolve the uncertainty. This problem is avoided in couple screening, as carriers with non-carrier partners are regarded as being negative on screening.

JOAN MORRIS

Lecturer in epidemiology and medical statistics

Department of Environmental and Preventive Medicine,
Wolfson Institute of Preventive Medicine,
St Bartholomew's and the Royal London School of
Medicine and Dentistry,
Queen Mary and Westfield College,
London EC1M 6BQ

- 1 Morris JK, Oppenheimer PM. Cost comparison of different methods of screening for cystic fibrosis. *Journal of Medical Screening* 1995;2:22-7.
- 2 Cuckle HS, Richardson GA, Sheldon TA, Quirke P. Cost effectiveness of antenatal screening for cystic fibrosis. *BMJ* 1995;311:1460-4. [With commentary by A Clarke.] (2 December.)
- 3 Haskey J. Step families and stepchildren in Great Britain. *Population Trends* 1994;76:17-28.
- 4 Wald NJ. Couple screening for cystic fibrosis. *Lancet* 1991;338:1318-9.

Couple screening would be easier for many centres

EDITOR,—H S Cuckle and colleagues provide further economic evidence supporting antenatal screening for cystic fibrosis.¹ The couple model is estimated to cost more than the sequential model, largely because of retesting in subsequent pregnancies if the woman's partner has changed. However, the estimate takes into account neither the cost nor the complexity of counselling and other contact with the patients in the sequential model. The cost of counselling would be modest, but locating each woman who was a carrier, explaining the need for and obtaining a sample from her partner, and subsequently explaining the results of the test would add complexity in decentralised health care settings. Furthermore, counselling 3% of couples, only one member of whom is a carrier, can raise anxiety with no prospect of definitive resolution by prenatal diagnosis. Some investigators report anxiety to be a continuing problem in the sequential model.

Besides avoiding these problems, the couple model requires that both the pregnant woman and the father agree to screening and submit samples at the outset. This simplifies the overall process, minimises further contact, and adds assurance that the decision to be screened is neither casual nor due to coercion. Genetic counselling is required for only the 0.1% of all couples (carrier woman with carrier partner) to whom definitive prenatal diagnosis can be offered.

Between June 1994 and December 1995 our group carried out a pilot study to evaluate antenatal screening for cystic fibrosis.² Enrolled couples lived in a sparsely populated region (Maine) and received antenatal care from 68 physicians at 38 health care sites. Before initiating the pilot study we determined that these sites could, without

difficulty, provide initial printed information and material for collecting samples, obtain informed consent, and answer general questions. The staff could not, however, offer the more sophisticated counselling necessary for people found to be carriers. The sequential model would require that the physician's office recontact each carrier woman, obtain her partner's sample for analysis, explain the need for counselling, and arrange it. This was viewed as burdensome. Particularly in the case of couples in which the woman was a carrier but her partner was not, geographic barriers and work schedules could restrict access to timely genetic counselling. These considerations led us to select the couple model for the pilot study.

The staff at the sites where antenatal care was given and a random subset of patients were surveyed at the end of the study to identify problems. Both patients and staff reported a high level of satisfaction. The couple model could thus more realistically be implemented in our setting.

RICHARD A DOHERTY
Director, genetics division

LINDA A BRADLEY
Director, cystic fibrosis screening laboratory

JAMES E HADDOW
Medical director

Foundation for Blood Research,
Scarborough,
ME 04070-0190,
USA

- 1 Cuckle HS, Richardson GA, Sheldon TA, Quirke P. Cost effectiveness of antenatal screening for cystic fibrosis. *BMJ* 1995;311:1460-4. [With commentary by A Clarke.] (2 December.)
- 2 Doherty RA, Palomaki GE, Kloza EM, Erickson JL, Dostal DA, Haddow JE. Prenatal screening for cystic fibrosis. *Lancet* 1994;343:172.

Authors should have used marginal analysis

EDITOR,—The paper by H S Cuckle and colleagues should aid purchasing decisions regarding screening for cystic fibrosis on the basis of only a single genetic marker.¹ The evaluation is, however, seriously flawed with respect to screening for multimations because the authors have fallen into the classic error of using average rather than marginal analysis.²

In table 1 the authors show that screening for a single mutation, with uptake of 75% and a detection rate of 80%, detects 384 affected pregnancies for a total cost of £17 758 000, giving a cost effectiveness ratio of roughly £46 000 per pregnancy detected. The authors go on to show, however, that if a multimation test is used then this results in an average cost effectiveness ratio of about £70 000. The authors should have used marginal analysis,² which is done as follows.

The single mutation test detects 80% (that is, 384) of affected pregnancies. If it is assumed that the multimation test increases the detection rate by 10% to 90%, this would result in 432 affected pregnancies being detected (that is, $(384/0.8) \times 0.9$). What the authors have done is to take the total cost of screening with the multimation test and divide it by the total number of affected pregnancies, which produces an average cost effectiveness ratio of £70 000, thus implying a total cost of £30 240 000 (that is, $432 \times £70 000$)—although there seems to be an error in the authors' calculations as substituting £33 for £16 in the figure leads to a total cost of £33 697 556).

What the authors should have done is take the incremental cost of multimation screening, which is £15 939 566 (that is, £33 697 566–£17 758 000) and divide this by the extra 48 affected pregnancies detected (that is, $432-384$), which results in a marginal cost effectiveness ratio of £332 074. This marginal ratio is nearly five times greater than the average ratio and is more likely to influence purchasers to buy the single mutation test

rather than the more expensive multimation test.

Purchasers might still have considered the multimation test on the basis of evidence contained in the present paper, as £70 000 is still less than the 25 year discounted (at 6%) excess NHS cost of treating a person with cystic fibrosis (assumed to be £8000 a year³), which is £104 026. If purchasers realised that they would actually be paying £332 074 per extra affected pregnancy detected, however, they would be less likely to fund the extra costs of multimation testing.

Inappropriate use of average rather than marginal analysis is all too common in published economic evaluations, particularly screening studies.²

DAVID J TORGERSON
Research fellow

National Primary Care Research and Development Centre,
Centre for Health Economics,
University of York,
York YO1 5DD

- 1 Cuckle HS, Richardson GA, Sheldon TA, Quirke P. Cost effectiveness of antenatal screening for cystic fibrosis. *BMJ* 1995;311:1460-4. [With commentary by A Clarke.] (2 December.)
- 2 Torgerson DJ, Spencer A. Marginal costs and benefits. *BMJ* 1996;312:35-6. (6 January.)

Study might be better described as a cost description of screening

EDITOR,—H S Cuckle and colleagues' paper on the cost effectiveness of antenatal screening for cystic fibrosis raises several important questions.¹ Firstly, their choice of cost effectiveness analysis rather than cost-benefit analysis makes an implicit assumption that the goal of a screening programme is to reduce births of affected infants and thus reduce health expenditure. This can be achieved only by introducing screening into a situation where there is high uptake (that is, antenatal clinics) and maximisation of the rate of subsequent termination of affected pregnancies. This is not the only model of screening. Indeed, it is one that explicitly limits reproductive choice in those women and couples who would not consider termination but might consider preimplantation diagnosis or artificial insemination by donor.

We know that a proportion of women in Britain would not consider termination of an affected pregnancy.² In their cost effectiveness analysis Lieu *et al* found that the proportion of women accepting termination of an affected pregnancy had a large effect on costs, particularly when it fell below 50%.³ In Cuckle and colleagues' example the cost per affected birth avoided would increase to £92 000 if therapeutic abortion was accepted in only half of the cases.

Lieu *et al* also showed that increasing costs of lifetime medical care for a patient with cystic fibrosis had a large effect on the cost effectiveness of a screening programme. Unfortunately, Cuckle and colleagues quote a single annual figure for medical care derived from a single unit treating adult patients. This does not account for the fact that care may be cheaper for children, who tend to be in better health than adults with cystic fibrosis, nor does it use discounting over the current median life expectancy of 28 years.⁴ Indeed, their study might be better described as a cost description of screening for cystic fibrosis, since effectiveness is not considered in great depth and factors known to affect cost effectiveness have been omitted from the sensitivity analysis.

This study makes other important assumptions, not the least of which is that a disease for which the life expectancy for the current birth cohort is probably at least 40 years should be prevented. The study shows what a programme that maximises termination of affected pregnancies might cost the NHS, but not that it is cost effective. It does not address the moral and ethical issues that such